Lilly's Retatrutide Phase 3 Trial: 26% Weight Loss Over 68 Weeks in Knee Osteoarthritis Patients, With Marked Pain Relief

Eli Lilly's experimental drug retatrutide improved both knee pain and body weight in a Phase 3 trial in knee osteoarthritis, according to results from the TRIUMPH study presented at the American College of Rheumatology's annual meeting in Orlando by University of Leeds researcher Philip Conaghan.
The 68-week trial enrolled 445 overweight adults with painful knee osteoarthritis and compared two strengths of the once-weekly injection against placebo. Among participants who completed the study, those on retatrutide lost an average of 26% of their body weight, versus 2% on placebo, alongside significant improvements in knee pain.
Tolerability data were reported at the same time: discontinuations due to adverse events were 18.2% in the higher-strength group, 13% in the lower-strength group and 6% (four people) on placebo. The researchers say the relationship between the weight loss and pain relief, and any long-term effect on the joint itself, will need further study.
Retatrutide is a next-generation metabolic drug candidate and is not yet approved anywhere. By extending the endpoints of weight-loss therapy to osteoarthritis symptoms, the trial points to a possible new approach for the large population living with both obesity and knee osteoarthritis, though regulatory review still lies ahead.
(Source: Eli Lilly and Company)
Source: Eli Lilly and Company
Published by GSM · USA (original Chinese edition)
Photo: 图片来源:Wikimedia Commons「Osteoarthritis left knee.jpg」(James Heilman, MD 摄,CC BY-SA 3.0),图中为左膝骨关节炎的医学影像 Image: Wikimedia Commons "Osteoarthritis left knee.jpg" (by James Heilman, MD, CC BY-SA 3.0), showing medical imaging of a left knee with osteoarthritis

